The trial is designed to evaluate the safety and tolerability of SB1518 in patients with chronic idiopathic myelofibrosis (CIMF) and is expected to enroll up to 50 patients.
The Phase I part of the study will assess the safety profile and evaluate the pharmacokinetic and pharmacodynamic activities of SB1518, and the Phase II component will assess the clinical benefits and continue to evaluate the safety profile of SB1518.
Jan-Anders Karlsson, CEO of S Bio, said: “We are pleased with the advancement of our JAK2 inhibitor into a Phase I/II clinical trial in Australia as it exemplifies the expansion of our company’s global development strategy.
“SB1518’s strengths are in its exciting anti-proliferative and anti-tumor activity, as demonstrated by a range of in vitro and in vivo models, as well as its excellent tolerability. We believe this compound may eventually provide oncologists with a much needed and improved option to treat patients suffering from CIMF.”